Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 14Carcinoma, Renal Cell 10Carcinoma, Non-Small-Cell Lung 7Carcinoma, Transitional Cell 4Neoplasms 3Neoplasm Metastasis 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Hepatocellular 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Skin Neoplasms 1Seminoma 1Sarcoma 1

Interventions

venetoclax 28Cytarabine 25Azacitidine 23Specimen Handling 21fludarabine 15Biopsy 13Injections 12Daunorubicin 11Cyclophosphamide 11fludarabine phosphate 10decitabine and cedazuridine drug combination 9Whole-Body Irradiation 9CPX-351 8Mycophenolic Acid 7Idarubicin 7Granulocyte Colony-Stimulating Factor 7Gemtuzumab 7ivosidenib 6Tacrolimus 6Stem Cell Transplantation 6Filgrastim 6Busulfan 6enasidenib 5X-Rays 5Melphalan 5Etoposide 5Decitabine 5Cyclosporine 5ruxolitinib 4olutasidenib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Ipilimumab × 30 days × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03600155 2026-05-15

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1 Completed
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡